217 - What Is the Optimal Therapy for My Patient With Bacteremia?

Saturday, October 14, 2023

10:30 AM – 11:45 AM US ET

Location: 160 ABC

All relevant financial disclosures have been mitigated.

Moderator(s)

A. Krishna Rao, MD, MS

Associate Professor
University of Michigan
Ann Arbor, MI, United States

Interactive Moderator(s)

Robert Bonomo, MD

Professor
CWRU School of Medicine
Cleveland, OH, United States
Sara Cosgrove, MD, MS

Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, Maryland, United States

Slides

Panelist(s)

Emily Spivak, MD, MHS (she/her/hers)

Associate Professor of Medicine
Internal Medicine, Division of Infectious Diseases
University of Utah School of Medicine
Salt Lake City, UT, United States
William Miller, M.D.

Assistant Professor
Infectious Diseases
Houston Methodist Research Institute
Houston, TX, United States
Emily Heil, PharmD, MS

Professor
Infectious Diseases
University of Maryland School of Pharmacy
Baltimore, MD, United States

Disclosure(s):

A. Krishna Rao, MD, MS: Merck and Company, Inc.: Grant/Research Support (Terminated); Rebiotix Inc.: Advisor/Consultant (Terminated); Seres Therapeutics Inc: Advisor/Consultant (Ongoing); Summit Therapeutics: Advisor/Consultant (Ongoing)

Robert A. Bonomo, MD: No financial relationships to disclose

Sara E. Cosgrove, MD, MS: Debiopharm: Advisor/Consultant (Ongoing); Duke Clinical Research Institute: Advisor/Consultant (Ongoing)

Emily S. Spivak, MD, MHS: No financial relationships to disclose

William R. Miller, M.D.: Merck and Company, Inc.: Grant/Research Support (Ongoing); UpToDate Wolters Kluwer Health: Honoraria (Ongoing)

Emily L. Heil, PharmD, MS: Wolters Kluwer-LexiComp: Advisor/Consultant (Ongoing)

CME Credits: Maximum of 1.25 hours of AMA PRA Category 1 Credit™
MOC Credits: Maximum of 1.25 hours of MOC Credit
CNE Credits: Maximum of 1.25 hours of ANCC Credit
ACPE Credits: ACPE 1.25 knowledge-based contact hours of pharmacy CE
ACPE Number: JA0007082-0000-23-002-L01-P

Learning Objectives:

At the conclusion of this session, participants will be able to:

describe the pros and cons of oral vs. parenteral treatments;
describe the impact that duration of therapy has on outcomes from bacteremia;
identify differences in Gram negative and Gram positive bacteremia treatment outcomes